Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | LNCB74 |
| Synonyms | |
| Therapy Description |
LNCB74 is an antibody-drug conjugate (ADC) comprising an antibody targeting VTCN1 (B7-H4) linked to monomethyl auristatin E, which potentially induces cytotoxicity against VTCN1 (B7-H4)-expressing tumor cells and antitumor activity (Journal for ImmunoTherapy of Cancer 2024;12). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| LNCB74 | LNCB-74|LNCB 74 | LNCB74 is an antibody-drug conjugate (ADC) comprising an antibody targeting VTCN1 (B7-H4) linked to monomethyl auristatin E, which potentially induces cytotoxicity against VTCN1 (B7-H4)-expressing tumor cells and antitumor activity (Journal for ImmunoTherapy of Cancer 2024;12). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06774963 | Phase I | LNCB74 | A Phase 1 Study of LNCB74 in Advanced Solid Tumors (LNCB74-01) | Recruiting | USA | 0 |